iPSC derived corneal endothelial cellular therapy

Cellusion have developed three main technologies for solving global cornea shortage issue, which are novel cell transplantation method for Bullous Keratopathy treatment, mass production technology to produce corneal endothelial cell from iPS cells, spheroid transplantation method to enhance the treatment efficacy. With these cellular technology breakthroughs, we will contribute to provide the clear vision of the future for worldwide patients.

Business Information:

​

Name of the company:

Cellusion Inc.

Year of establishment:

2015

Location of the headquarters:

Tokyo, JP

Other key location(s):

​

Spinout from:

​

Year of establishment:

2015

Cellusion owns IP and technologies to develop and obtain iPS-derived corneal endothelial cells suitable for corneal transplantation. They aim to derive enough therapeutic cells to treat thousands of patients from a single batch.

Company website:

​

https://cellusion.jp/en/

​

Technology validation:

Technology readiness level (TRL)

5

CEO message:

Value if IP (patents)

Cellusion always welcomes to join our team as whoever solving global blindness issue together. Regardless of collaboration or investment etc., please feel free to contact us. Why don’t we discuss what we can do together?

​

Current business stage:

Series A stage
Series B stage

Next investment required:

$2m to $3m

Target exit style:

IPO in Japan
Trade sales

Clinical study level (if relevant):

​

Shin Hatou

Technical literatures:

To be updated

Biospire's roles:

​